관련문헌 등
1)Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14e (2023)
2)Goldman-Cecil Medicine 27th (2024)
3)EUROGUIDERM GUIDELINE FOR THE SYSTEMIC TREATMENT OF PSORIASIS VULGARIS (2023)
4)British association of dermatologist guideline (2023)
5)Kristian Reich et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial The Lancet 2021;397;pages 487-98.
6)Akihiko Asahina et al. Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study Dermatology and Therapy 2023;13;pages 751-768.
7)Kenneth B Gordon et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial The Lancet 2021;397;pages 475-86.
8)R.B. Warren et al. Bimekizumab versus Adalimumab in Plaque Psoriasis The NEW ENGLAND JOURNAL of MEDICINE 2021;385;pages 130-41.
9)Diamant Thaci et al. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial British Journal of Dermatology 2023;188;pages 22-31.
10)Bruce Strober et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial British Journal of Dermatology 2023;188;pages 749-759.
11)Kenneth B.Gordon et al. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials British Journal of Dermatology 2024;190;pages 477-485.
12)Kristian Reich et al. Bimekizumab versus Secukinumab in Plaque Psoriasis The NEW ENGLAND JOURNAL of MEDICINE 2021;385;pages 142-52.
13)Bruce Strober et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial Journal of the American Academy of Dermatology 2023;89;pages 486-495.
14)Sang Woong Youn et al. Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study The Journal of Dermatology 2024;00;pages 1-12.
15)Shanshan Xu et al. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis Journal of the Gernam Society of Dermatology 2021;Volume19;pages 47-56.
16)April Armstrong et al. Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis Dermatology and Therapy 2022;Volume12;pages 1777-1792.
17)April Armstrong et al. Long-Term Benefit？Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis Dermatology and Therapy 2022;Volume12;pages 167-184.
18)Emilie Sbidian et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review). Cochrane Database of Systematic Reviews (2023)
19)대한피부과학회(2024/10/11-1, 2024.10.11.)
20)NICE (2021.9.1.)
21)SMC (2021.10.8.)
22)PBAC (2023.3.23.)
23)CADTH (2022.3.30.)